Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,174 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Imaging Agent Clear all
Completed Not applicable Interventional

A Pilot Study: Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy

NCT01911650
View directory record Official record
Conditions
Achilles Tendinitis
Interventions
Autologous Platelet Rich Plasma, Ultrasound Imaging, Quality of Life Questionnaires
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 3 Interventional Results available

Regadenoson Real Time Perfusion Imaging Trial-Optison

NCT01489176
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Perfusion Abnormalities
Interventions
Regadenoson; Optison
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 24, 2026, 8:57 AM EDT
Recruiting Phase 4 Interventional

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

NCT04265430
View directory record Official record
Conditions
Malignant Oral Cavity Neoplasm, Malignant Skull Base Neoplasm, Osteoradionecrosis
Interventions
Contrast Agent, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cediranib Maleate, Computed Tomography, Echocardiography Test, Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Pharmacological Study, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
337
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
[68Ga]Ga-NNS309, [177Lu]Lu-NNS309
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

NCT04054986
View directory record Official record
Conditions
Breast Cancer
Interventions
F-Var3 PET/CT, Blood draw
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 2 Interventional Results available

Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

NCT01710254
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease
Interventions
Regadenoson MRI, Gadobenate dimeglumine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

NCT01379183
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 24, 2026, 8:57 AM EDT
Active, not recruiting Phase 3 Interventional

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

NCT04579224
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
448
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Completed No phase listed Observational

Nicotinic Receptor Levels After Stopping Smoking

NCT01704573
View directory record Official record
Conditions
Nicotine Addiction
Interventions
2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 24, 2026, 8:57 AM EDT
Terminated Not applicable Interventional Results available

Personalized Interactive Laser Therapy of Port Wine Stain

NCT00782483
View directory record Official record
Conditions
Port Wine Stain
Interventions
ThermoVision A20M Infrared Camera, ScleroPLUS, 3D Digital Camera
Device
Lead sponsor
University of Arkansas
Other
Eligibility
3 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Radiation Dose in Humans From Orally Administered Tc99m-Heparin

NCT04069429
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Computerized Tomography scan, Single Photon Emission Computed Tomography scans, Technetium Tc 99M, Planar Images, Esophagogastroduodenoscopy
Radiation · Drug · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 24, 2026, 8:57 AM EDT
Not listed Phase 2 Interventional

Novel Gallium Imaging in Hepatocellular Carcinoma

NCT03116945
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
68Gallium Citrate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 24, 2026, 8:57 AM EDT
Enrolling by invitation Not applicable Interventional

Comparing a New 3D Technology Used to Measure Thyroid Nodule Volume to Standard Ultrasound

NCT07178080
View directory record Official record
Conditions
Thyroid Nodules, Thyroid Nodule
Interventions
PIUR tUS Infinity Ultrasound
Device
Lead sponsor
Sarasota Memorial Health Care System
Other
Eligibility
22 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 24, 2026, 8:57 AM EDT
Not listed No phase listed Observational

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis

NCT05369546
View directory record Official record
Conditions
Breast Cancer
Interventions
q3CB
Diagnostic Test
Lead sponsor
University of Hawaii
Other
Eligibility
20 Years to 85 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Tampa, Florida • Hilo, Hawaii • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 24, 2026, 8:57 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CT TAVR Abdomen Study

NCT05758701
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Iodinated Contrast Agent (Omnipaque), Dual Energy CT
Combination Product · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 24, 2026, 8:57 AM EDT
Not yet recruiting Early Phase 1 Interventional

[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

NCT07026981
View directory record Official record
Conditions
Head and Neck Cancer, Pancreatic Cancer, Cancer Pancreas
Interventions
[Ga-68]MTP220 PET/CT Scan
Drug
Lead sponsor
Qiubai Li
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 3 Interventional

IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery

NCT05954767
View directory record Official record
Conditions
Ureter Injury
Interventions
IS-001
Drug
Lead sponsor
Intuitive Surgical
Industry
Eligibility
16 Years to 75 Years · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Newport Beach, California • Miami, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

NCT01370265
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine, N-13 ammonia
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 24, 2026, 8:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuro-ocular Baselines in a Sports Setting

NCT03653936
View directory record Official record
Conditions
Wave Form Signals Coming From the Eye in a Healthy Cohort
Interventions
HITT device
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
11 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 24, 2026, 8:57 AM EDT
Completed Phase 1 Interventional

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

NCT06863233
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions
Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 24, 2026, 8:57 AM EDT
Suspended Phase 2 Interventional

Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy

NCT03952598
View directory record Official record
Conditions
Glioma, Gliomas, High Grade Glioma, Malignant Glioma, Low Grade Glioma
Interventions
HP 13C Pyruvate, 3T MRI scanner
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 8:57 AM EDT